首页> 外文期刊>RSC Advances >FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy
【24h】

FDPP–HA as a theranostic agent for cancer-targeted fluorescence imaging and photodynamic therapy

机译:FDPP–HA作为治疗癌症的荧光成像和光动力疗法的治疗药物

获取原文
           

摘要

In clinics, for photodynamic therapy (PDT) it is challenging to achieve photosensitizers with properties of high singlet oxygen quantum yield, tumor targeting and fluorescence imaging simultaneously. Herein, a furan flanked diketopyrrolopyrrole (FDPP) molecule, with good singlet oxygen quantum yield (~26%), is covalently connected to hyaluronic acid (HA) to obtain a water-soluble photosensitizer (FDPP–HA), which presents good specific targeting to HCT-116 tumor cells both in vitro and in vivo. FDPP–HA also exhibits excellent biocompatibility, low dark toxicity and high phototoxicity, which can effectively inhibit the tumor growth in vivo by PDT. The design of FDPP–HA in this work provides a general strategy for cancer target-specific fluorescence imaging and PDT.
机译:在临床上,对于光动力疗法(PDT)来说,要实现具有高单线态氧量子产率,肿瘤靶向和荧光成像的特性的光敏剂是一项挑战。在此,将具有良好单线态氧量子产率(〜26%)的呋喃侧链二酮基吡咯并吡咯(FDPP)分子与透明质酸(HA)共价连接以获得水溶性光敏剂(FDPP-HA),其具有良好的特异性靶向体外 体内的HCT-116肿瘤细胞。 FDPP-HA还具有优异的生物相容性,低暗毒性和高光毒性,可有效抑制PDT体内肿瘤的生长。这项工作中FDPP-HA的设计为癌症靶标特异性荧光成像和PDT提供了一般策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号